Since some specific splice isoforms are used as potential tumor markers and therapeutic targets, it is reasonable to design inhibitors targeting splicing factors.190 In fact, SF3B1, having the highest mutation degree in various hematological malignancies, is often used as a target for cancer treatment. The gene discussed is SF3B1; the disease is hematologic disorder.